The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Design Therapeutics Inc shares valued at $891,600 were purchased by Logos Global Master Fund LP on Nov 18 ’25. At $7.43 per share, Logos Global Master Fund LP acquired 120,000 shares.
Also, Logos Global Master Fund LP purchased 620,000 shares, netting a total of over 4,377,200 in proceeds.
Before that, Logos Global Master Fund LP had added 415,000 shares to its account. In a trade valued at $2,851,050, the Director bought Design Therapeutics Inc shares for $6.87 each.
As published in a research note from Leerink Partners on December 03, 2025, Design Therapeutics Inc [DSGN] has been rated up from a Market perform to an Outperform and the price target has been revised to $14. Analysts at Craig Hallum started covering the stock with ‘”a Buy”‘ outlook in a report released in early December. As of November 20, 2025, RBC Capital Mkts has increased its “Sector perform” rating to a “an Outperform” for DSGN. Earlier on May 07, 2024, Piper Sandler upgraded its rating. Their new recommendation was “an Overweight” for DSGN stock which previously was a “a Neutral”.
Analyzing DSGN Stock Performance
On last trading session, Design Therapeutics Inc [NASDAQ: DSGN] rose 9.28% to $9.77. The stock’s lowest price that day was $9.05, but it reached a high of $9.99 in the same session. During the last five days, there has been a surge of approximately 3.83%. Over the course of the year, Design Therapeutics Inc shares have jumped approximately 62.83%. Shares of the company reached a 52-week high of $10.00 on 12/03/25 and a 52-week low of $2.60 on 04/11/25.
Support And Resistance Levels for Design Therapeutics Inc (DSGN)
According to the 24-hour chart, there is a support level at 9.21, which, if violated, would cause prices to drop to 8.66. In the upper region, resistance lies at 10.16. The next price resistance is at 10.56. RSI (Relative Strength Index) is 71.58 on the 14-day chart, showing overbought technical sentiment.
Is Design Therapeutics Inc subject to short interest?
Stocks of Design Therapeutics Inc saw a sharp rise in short interest on 2025-11-14 jumping by 95570.0 shares to 2.0 million. Data from Yahoo Finance shows that the short interest on 2025-10-15 was 1.91 million shares. A jump of 4.77% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 5.39 of the overall float, the days-to-cover ratio (short ratio) jumped to 5.39.
Which companies own the most shares of Design Therapeutics Inc (DSGN)?
In terms of Design Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 14.5 in the next 12 months, up nearly 62.19% from the previous closing price of $8.94. Analysts anticipate Design Therapeutics Inc stock to reach 15 by 2025, with the lowest price target being 14. In spite of this, 2 analysts ranked Design Therapeutics Inc stock as Buy at the end of 2025. On November 14, 2023, Piper Sandler assigned a price target of “a Neutral” to the stock and downgraded coverage with a $6.
